Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

• ClinicalTrials.gov Identifier: NCT01585688
• Recruitment Status: Terminated
• First Posted: April 26, 2012
• Last Update Posted: October 8, 2021
• Sponsor: Gilead Sciences
• Information provided by (Responsible Party): Gilead Sciences

Study Description

Brief Summary:

The primary objectives are to evaluate the safety and tolerability of hLL1-DOX, and to determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated dosing schedule). The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.

Condition or disease	Intervention/treatment	Phase
Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia	Drug: hLL1-DOX (IMMU-115)	Phase 1; Phase 2

Detailed Description:

Patients receive hLL1-DOX at one of 4 dose levels administered on Days 1, 4, 8 and 11 of 21-day treatment cycles which are continued in the absence of progression or unacceptable toxicity up to a total of 8 cycles. After treatment, follow-up will be done at 4, 8 and 12 weeks post-treatment and will continue to be done every 3 months for up to 2 years.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 13 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
• Actual Study Start Date: August 2012
• Actual Primary Completion Date: November 2016
• Actual Study Completion Date: October 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: hLL1-DOX	Drug: hLL1-DOX (IMMU-115); hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.; Other Name: IMMU-115

Outcome Measures

Primary Outcome Measures :

1. Evaluate the safety and tolerability of hLL1-DOX [ Time Frame: These assessments will be done routinely during treatment & changes at 4, 8 & 12 weeks after treatment ]
   NCI CTCAE version 4.0 is used to grade all adverse events
2. All patients who were treated and meet the efficacy criteria for response assessment will be included in the analysis of efficacy [ Time Frame: During treatment and the changes at 4, 8 and 12 weeks after treatment and then every 3 months for up to 2 years ]

   For the primary efficacy evaluations, the proportion of responders (defined as patients with a best response of PR or CR) will be tabulated for each dose level. In addition, the progression-free survival (PFS, as measured from start of treatment to disease progression, death or last follow-up) will be summarized using Kaplan-Meier survival analysis methods.

   Similarly, for responders at each dose level, the duration of response (DR, as measured from time of first response to relapse or last follow-up) will also be summarized using Kaplan- Meier survival analysis methods, if appropriate.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female, age ≥ 18 years
• Able to provide signed, informed consent
• Histologically confirmed diagnosis of recurrent B-cell non-Hodgkin's lymphoma (any histology by WHO criteria) or recurrent chronic lymphocytic leukemia (by NCI criteria) (Reference Appendix C)
• Received at least one prior treatment with standard therapy (previous antibody therapy is acceptable)
• Measurable disease at least one lesion ≥ 1.5 cm for NHL and ALC > 5,000 for CLL

• Adequate performance status (≥ 70 Karnofsky scale) with an estimated life expectancy of at least 6 months

  --Documented negative hepatitis B screen, per NCCN guidelines (hepatitis B surface antigen/antibodies, core antigen/antibodies, hepatitis B e-antigen)

• At least 12 weeks beyond stem cell transplant and 4 weeks beyond chemotherapy or immunotherapy, major surgery, other experimental treatments, or radiation therapy to the index lesions, and with all acute toxicities from prior therapy resolved to less than Grade 2 toxicity by NCI CTC version 4.0
• Laboratory parameters:

Adequate hematology without ongoing transfusional support Hemoglobin >/= 10 g/dL Absolute neutrophil count >/= 1.5 x 10 9/L Platelets >/= 75 x 10 9/L Creatinine and bilirubin </= 1.5 x IULN AST and ALT </= 2.5 x IULN

-Adequate cardiac function (MUGA scan or 2-D ECHO with LVEF ≥ 55%, EKG with no medically relevant arrhythmia uncontrolled on medications)

Exclusion Criteria:

• -Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
• Women of childbearing potential and fertile men who are not practicing or who are unwilling to practice birth control while enrolled in the study until at least 12 weeks after the last milatuzumab infusion
• Prior therapy with other human or humanized monoclonal antibodies, unless HAHA tested and negative
• Prior treatment with trastuzumab
• Bulky disease by CT, defined as any single mass > 10 cm in its greatest diameter
• Known HIV positive or active hepatitis B or C, or presence of hepatitis B surface antigens or presence of hepatitis C antibody
• New York Heart Classification III or IV heart disease (see Appendix G). Other severe cardiovascular or cardiopulmonary disease, including COPD
• Baseline BNP > 2 x IULN
• Patients with uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities will be excluded
• Patients with recent (≤ 6 months) cardiac angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias will be excluded
• Known autoimmune disease or presence of autoimmune phenomena
• At least 7 days beyond any infection requiring intravenous antibiotic use (Oral antibiotics may be administered prophylactically as clinically indicated)
• Systemic corticosteroids within 2 weeks, except low dose regimens (prednisone, ≤ 20 mg/day, or equivalent) which may continue if unchanged
• Substance abuse or other concurrent medical or psychiatric conditions that, in the Investigator's opinion, could confound study interpretation or affect the patient's ability to tolerate or complete the study

Contacts and Locations

Locations

United States, Delaware

Helen F. Graham Cancer Center

Newark, Delaware, United States, 19713

United States, Florida

MD Anderson Cancer Center Orlando

Orlando, Florida, United States, 32806

United States, Indiana

IU Health Goshen Center for Cancer Care

Goshen, Indiana, United States, 46526

United States, Massachusetts

UMass Memorial Cancer Center of Excellence

Worcester, Massachusetts, United States, 01605

United States, New Jersey

John Theurer Cancer Center Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

United States, Texas

U.T. MD Anderson Cancer Center Houston

Houston, Texas, United States, 77030

Sponsors and Collaborators

Gilead Sciences

Investigators

• Study Director: Pius P Maliakal, PhD; Gilead Sciences
• Study Chair: Francois Wilhelm, MD,PhD; Gilead Sciences

More Information

• Responsible Party: Gilead Sciences
• ClinicalTrials.gov Identifier: NCT01585688
• Other Study ID Numbers: IM-T-hLL1-DOX-02
• First Posted: April 26, 2012
• Last Update Posted: October 8, 2021
• Last Verified: February 2020

Keywords provided by Gilead Sciences:

NHL; CLL

Additional relevant MeSH terms:

Lymphoma; Leukemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphoid; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Leukemia, B-Cell; Chronic Disease; Disease Attributes; Pathologic Processes